DDInter419 DDInter172
Clozapine is a tricyclic dibenzodiazepine, classified as an atypical antipsychotic agent. Clozapine displays affinity to various neuroreceptors with a particularly low affinity to the dopamine receptors, thus breaking the mold of first-generation antipsychotics and deeming it "atypical".. This low affinity to dopamine receptors results in fewer extrapyramidal side effects, especially tardive dyskinesia. However, its promiscuity toward the muscarinic and adrenergic receptors can result in other side effects, notably gastrointestinal hypomotility and orthostatic hypotension. [L905,A215552]. Despite its effectiveness in treating both positive and negative symptoms of schizophrenia, clozapine was briefly removed from the market in various jurisdictions in 1970 due to severe agranulocytosis.[A256713,A256718] However, continued evidence of its effectiveness led to clozapine's eventual reintroduction, although
Belatacept is a soluble fusion protein, which links the extracellular domain of human cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) to the modified Fc (hinge, CH2, and CH3 domains) portion of human immunoglobulin G1 (IgG1). Structurally, abatacept is a glycosylated fusion protein with a MALDI-MS molecular weight of 92,300 Da and it is a homodimer of two homologous polypeptide chains of 357 amino acids each. It is produced through recombinant DNA technology in mammalian CHO cells. The drug has activity as a selective co-stimulation modulator with inhibitory activity on T lymphocytes. It is approved for the treatment of rheumatoid arthritis. Belatacept selectively blocks the process of T-cell activation. It was developed by Bristol-Myers-Squibb. Belatacept is only 2 amino acids different from abatacept (Orencia). FDA approved on June 15, 2011.
Clozapine {u} (Compound) resembles {v} (Compound) Trifluoperazine
Clozapine {u} (Compound) resembles {v} (Compound) Prochlorperazine
Clozapine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Azatadine
Clozapine {u} (Compound) binds {v} (Gene) CYP2D6
Clozapine {u} (Compound) upregulates {v} (Gene) ST3GAL5
Clozapine {u} (Compound) palliates {v} (Disease) bipolar disorder
Clozapine {u} (Compound) downregulates {v} (Gene) POLR2I
Clozapine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Clozapine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Caffeine
Clozapine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Trospium
Clozapine (Compound) resembles Trifluoperazine (Compound)
Clozapine (Compound) resembles Prochlorperazine (Compound)
Clozapine may cause a moderate interaction that could exacerbate diseases when taken with Azatadine
Clozapine (Compound) binds CYP2D6 (Gene)
Clozapine (Compound) upregulates ST3GAL5 (Gene)
Clozapine (Compound) palliates bipolar disorder (Disease)
Clozapine (Compound) downregulates POLR2I (Gene)
Clozapine may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Clozapine may cause a minor interaction that can limit clinical effects when taken with Caffeine
Clozapine may cause a moderate interaction that could exacerbate diseases when taken with Trospium